Table 2.
Demographics, clinical data, and assessment subject to pain.
| Demographics, clinical data, assessment |
MOG-IgG-pos. NMOSD patients |
|
AQP4-IgG-pos. NMOSD patients |
p value |
AQP4/MOG-IgG-neg. NMOSD patients |
|||
|---|---|---|---|---|---|---|---|---|
| With paina | Without pain | p valuePatients with/without pain | With paina | Without pain | p valuePatients with/without pain | MOG-IgG-pos./AQP4-IgG-pos. NMOSD patients with pain | With paina | |
| N of patients (f/m) | 12 (9/3) | 2 (1/1) | 1 | 24 (21/3) | 5 (5/0) | 0.309 | 6 (5/1) | |
| Age (years) | 46 (21–79) | 41 (34–48) | 0.659 | 50 (20–71) | 40 (31–72) | 0.758 | 0.436 | 53 (24–71) |
| EDSS (0–10) | 2.25 (1–6) | 2 (2) | 0.473 | 3.5 (0–7) | 2.5 (1.5–4) | 0.382 | 0.112 | 3.25 (2.5–5) |
| History of myelitis, n | 8 | 2 | 22 | 5 | 1 | 0.009 b | 6 | |
| Pain type, n (%) | ||||||||
| Neuropathic pain | 5 (41.67%) | 19 (79.17%) | 0.198 | 5 (83.33%) | ||||
| Headache/Neck pain | 5 (41.67%) | 5 (20.83%) | 0.252 | 2 (33.33%) | ||||
| Musculoskeletal | 0 | 0 | NA | 1 (16.67%) | ||||
| Spasticity | 1 (8.33%) | 3 (12.50%) | 1 | 1 (16.67%) | ||||
| Increased tone | 3 (25.0%) | 7 (29.17%) | 0.376 | 2 (33.33%) | ||||
| Othersb | 2 (16.67%) | 4 (16.67%) | 1 | 1 (16.67%) | ||||
| Pain medication, n (%) | 4 (33.33%) | 9 (37.50%) | 0.702 | 3 (50.0%) | ||||
| >1 pain medication | 0 | 4 (16.67%) | 1 | 1 (16.67%) | ||||
| NSAID | 1 | 2 | 0 | |||||
| Opioids | 0 | 3 | 0 | |||||
| Anticonvulsants | 1 | 7 | 3 | |||||
| Antidepressants | 0 | 2 | 1 | |||||
| Muscle relaxants | 1 | 1 | 0 | |||||
| VAS General Health (0–100) | 47.50 (51.50) (5–76) | NA | NA | 43.29 (35) (3–100) | 26.8 (21) (0–51) | 0.270 | 0.679 | 52.50 (58) (17–72) |
| VAS Fatigue (0–100) | 46.83 (55.50) (0–76) | NA | NA | 43.29 (44.50) (1–100) | 25.2 (20) (0–66) | 0.145 | 0.753 | 53.83 (54) (33–76) |
| SF-36 PCS (84.15 (90) (0–100)) |
42.27 (40.98) (21.49–57.62) |
56.64 (56.64) (56.64) |
0.333 | 39.92 (44.27) (16.58–56.58) |
43.23 (43.16) (30.20–57.52) |
0.518 | 0.687 | 38.49 (37.16) (19.51–55.38) |
| SF-36 MCS (74.74 (80) (0–100)) |
42.48 (39.07) (27.30–58.99) |
55.18 (55.18) (55.18) |
0.667 | 45.25 (46.46) (18.67–60.64) |
51.77 (50.77) (45.17–56.86) |
0.201 | 0.430 | 46.76 (49.74) (35.97–52.95) |
| BDI-II (0–63) | 10.33 (7) 1–25 | 0.5 (0.5) (0–1) | 0.022 b | 10.04 (8) 0–26 | 5.8 (4) (1–14) | 0.245 | 1 | 15.67 (15) 6–24 |
AQP4-IgG-pos.: aquaporin-4-immunoglobulin-G-positive; BDI-II: Beck Depression Inventory II; EDSS: Expanded Disability Status Scale; f/m: female/male; MCS: Mental Component Summary; MOG-IgG-pos.: myelin-oligodendrocyte-glycoprotein-immunoglobulin-G-positive; N, n: number; NMOSD: neuromyelitis optica spectrum disorder; NSAID: nonsteroidal anti-inflammatory drug; PCS: Physical Component Summary; SF-36: Short Form 36 Health Survey; VAS: visual analog scale.
aPatients suffering from present pain or pain during the last four weeks.
bConnective tissue disease, arthralgia of unknown origin, vasculitis; Age, EDSS: median, (range); others: mean, (median), (range); p value: Fisher exact test for pain type, pain medication; p value others: Mann-Whitney U test; Significant p values are indicated in bold.